Madhav Vasanthavada

SVP, Chief Commercial Officer at Abeona Therapeutics

Speaker

Madhav Vasanthavada is Chief Commercial Officer at Abeona Therapeutics, where he is leading the commercialization of ZEVASKYN, a cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), an ultra-rare skin disease. Madhav brings more than 20 years of biopharmaceutical leadership delivering product launches, pricing and market access strategies, revenue growth, investor engagement, business development, and global cross-functional execution across Abeona, Celgene/Bristol Myers Squibb, Bayer, and Novartis. He holds a Ph.D. from the University of Rhode Island and an MBA from Harvard Business School.